Immune Regulation raises £40.6m Series B funding led by Morningside Ventures
The Boston investor backs the clinical stage biotechnology firm to advance its immune-resetting therapies.
Immune Regulation is a clinical stage biotechnology company developing therapies to reset the immune system for inflammatory and immunological diseases. The firm operates across the United States and the United Kingdom.
Immune Regulation has secured £40.6m in a Series B equity financing round led by Morningside Ventures. The funding includes participation from existing investor 24Haymarket and advance subscription funds from private investors led by Metellus AG.
The capital will be used to accelerate the development of the company drug product candidates designed to reset the immune system from a pro-inflammatory state to a balanced state. The financing supports upcoming phase 2 clinical studies for lead assets targeting rheumatoid arthritis, allergic disease, and COVID-19 related acute respiratory distress syndrome.
From the founder
"We have two clinical stage drug product candidates, '1805 and '1104, that have demonstrated impressive efficacy and safety data in phase 2a clinical studies on Rheumatoid Arthritis and Allergic Disease respectively and we are delighted to have Morningside as a partner to advance our programs,"
Jonathan Rigby
Group CEO at Immune Regulation
Investor perspective
"After extensive due diligence, Morningside concluded that Immune Regulation has drug products with significant potential to treat autoimmune and allergic diseases,"
Isaac Cheng
M.D., Morningside
Use of funds
- 01Fund research and development
- 02Grow the team
Investors
Categories
About the company
Immune Regulation
Developing first-in-class immune-resetting therapies for autoimmune and allergic conditions.